XTX Topco’s VistaGen Therapeutics VTGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$13.4K Sell
43,462
-74,918
-63% -$19K ﹤0.01% 3790
2026
Q2
$26.8K Sell
118,380
-34,469
-23% -$20.8K ﹤0.01% 3851
2026
Q1
$87.4K Buy
+152,849
New +$92.9K ﹤0.01% 3146
2025
Q4
– Sell
-69,712
Closed -$247K – 3861
2025
Q3
$247K Buy
+69,712
New +$208K 0.01% 1665
2022
Q3
– Sell
-2,294
Closed -$61K – 1412
2022
Q2
$61K Sell
2,294
-758
-25% -$26.8K 0.02% 727
2022
Q1
$114K Buy
+3,052
New +$133K 0.05% 496

Other funds holding VTGN

XTX Topco's VTGN Position: Q3 2026 in Review

XTX Topco reduced its VistaGen Therapeutics (VTGN) stake by 63% in Q3 2026, selling an estimated $19K and leaving 43,462 shares worth $13.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3790.

XTX Topco first reported a position in VTGN in Q1 2022 and has held it in 6 quarters since. The position peaked at $247K in Q3 2025. 42 funds tracked by Wall St. Rank hold VTGN as of Q3 2026.

  • XTX Topco held 43,462 shares of VistaGen Therapeutics worth $13.4K as of Q3 2026.
  • XTX Topco sold 74,918 VistaGen Therapeutics shares in Q3 2026, an estimated $19K.
  • VistaGen Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q3 2026, its #3790 holding.
  • XTX Topco first reported a position in VistaGen Therapeutics in Q1 2022 and has held it in 6 quarters since.
  • XTX Topco's VistaGen Therapeutics position peaked at $247K in Q3 2025.
  • 42 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2026.

Based on XTX Topco's 13F filing for Q3 2026, filed 16 Nov 2026.